Root Financial Partners’s INmune Bio INMB Stock Holding History

Root Financial Partners’s Portfolio INMB Stock Details INMB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-87	Closed	-$98	–	1762
2026 Q1	$98	Buy	+87	New	+$124	﹤0.01%	3285

Other funds holding INMB

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Root Financial Partners's INMB Position: Q2 2026 in Review

Root Financial Partners sold out of INmune Bio (INMB) in Q2 2026, closing a stake of 87 shares — an estimated $98 sold.

Root Financial Partners first reported a position in INMB in Q1 2026 and held it in 1 quarter. The position peaked at $98 in Q1 2026. 82 funds tracked by Wall St. Rank hold INMB as of Q2 2026.

Root Financial Partners reported no remaining INmune Bio position as of Q2 2026 after selling out during the quarter.
Root Financial Partners sold 87 INmune Bio shares in Q2 2026, an estimated $98.
Root Financial Partners first reported a position in INmune Bio in Q1 2026 and held it in 1 quarter.
Root Financial Partners's INmune Bio position peaked at $98 in Q1 2026.
82 funds tracked by Wall St. Rank held INmune Bio as of Q2 2026.

Based on Root Financial Partners's 13F filing for Q2 2026, filed 29 Jul 2026.